ABBV vs. AZN, NVS, ABT, LLY, JNJ, MRK, PFE, BMY, ZTS, and RPRX
Should you be buying AbbVie stock or one of its competitors? The main competitors of AbbVie include AstraZeneca (AZN), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceutical preparations" industry.
AbbVie (NYSE:ABBV) and AstraZeneca (NASDAQ:AZN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings.
70.2% of AbbVie shares are owned by institutional investors. Comparatively, 20.4% of AstraZeneca shares are owned by institutional investors. 0.3% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
AstraZeneca has lower revenue, but higher earnings than AbbVie. AstraZeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.
AstraZeneca has a net margin of 13.30% compared to AbbVie's net margin of 11.02%. AbbVie's return on equity of 179.47% beat AstraZeneca's return on equity.
AbbVie has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.
AbbVie pays an annual dividend of $6.20 per share and has a dividend yield of 3.8%. AstraZeneca pays an annual dividend of $1.93 per share and has a dividend yield of 2.5%. AbbVie pays out 184.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AstraZeneca pays out 94.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
AbbVie received 1246 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 73.10% of users gave AbbVie an outperform vote while only 58.95% of users gave AstraZeneca an outperform vote.
In the previous week, AbbVie had 6 more articles in the media than AstraZeneca. MarketBeat recorded 37 mentions for AbbVie and 31 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 0.78 beat AbbVie's score of 0.49 indicating that AstraZeneca is being referred to more favorably in the news media.
AbbVie currently has a consensus target price of $176.14, suggesting a potential upside of 9.24%. AstraZeneca has a consensus target price of $88.00, suggesting a potential upside of 12.79%. Given AstraZeneca's higher possible upside, analysts plainly believe AstraZeneca is more favorable than AbbVie.
Summary
AbbVie beats AstraZeneca on 14 of the 20 factors compared between the two stocks.
Get AbbVie News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
